553 research outputs found
Five-year follow-up of Japanese patients with Paget's disease of the bone after treatment with low-dose oral alendronate: a case series
<p>Abstract</p> <p>Introduction</p> <p>Paget's disease of the bone is characterized by focal abnormalities of increased bone turnover affecting one or more sites throughout the skeleton. Although this disease is rare in Japan, it is common in western and southern Europe, and among British migrants in Australia and New Zealand. Bisphosphonates have been widely used for the treatment of Paget's disease of the bone and are considered to be the treatment of choice. However, there have been few reports on the long-term follow-up examination of patients after their treatment with bisphosphonates.</p> <p>Case presentation</p> <p>We report the treatment with a low dose of oral alendronate (5 mg per day) which was effective in reducing bone turnover and pain over the five-year follow-up period in two Japanese patients, a 66-year-old man and a 68-year-old woman, with Paget's disease of the bone. Furthermore, in one patient, no clinical symptoms, such as bone pain or increases in serum total alkaline phosphatase and urinary N-terminal telopeptide of type I collagen as markers of bone turnover, were observed over the patient's five-year follow-up period.</p> <p>Conclusions</p> <p>To the best of our knowledge, this is the first report of a long-term follow-up of patients with Paget's disease of the bone after a six-month treatment with low-dose oral alendronate (5 mg per day).</p
Baseline observations from the POSSIBLE EU® study: characteristics of postmenopausal women receiving bone loss medications
Summary: Prospective Observational Scientific Study Investigating Bone Loss Experience in Europe (POSSIBLE
EU®) is an ongoing longitudinal cohort study that utilises
physician- and patient-reported measures to describe the
characteristics and management of postmenopausal women
on bone loss therapies. We report the study design and
baseline characteristics of 3,402 women recruited from
general practice across five European countries.
Purpose The POSSIBLE EU® is a study describing the
characteristics and management of postmenopausal women
receiving bone loss medications.
Methods: Between 2005 and 2008, general practitioners
enrolled postmenopausal women initiating, switching or
continuing treatment with bone loss treatment in France,
Germany, Italy, Spain and the UK. Patients and physicians
completed questionnaires at study entry and at 3-month
intervals, for 1 year.
Results: Of 3,402 women enrolled (mean age 68.2 years
[SD] 9.83), 96% were diagnosed with low bone mass; 55%
of these using dual energy X-ray absorptiometry. Most
women (92%) had comorbidities. Mean minimum T score
(hip or spine) at diagnosis was −2.7 (SD 0.89; median −2.7
[interquartile range, −3.2, −2.2]) indicating low bone
mineral density. Almost 40% of the women had prior
fractures in adulthood, mostly non-vertebral, non-hip in
nature, 30% of whom had at least two fractures and more
than half experienced moderate/severe pain or fatigue.
Bisphosphonates were the most common type of bone loss
treatment prescribed in the 12 months preceding the study.
Conclusions POSSIBLE EU® characterises postmenopausal
women with low bone mass, exhibiting a high rate of
prevalent fracture, substantial bone fragility and overall
comorbidity burden. Clinical strategies for managing
osteoporosis in this population varied across the five
participating European countries, reflecting their different
guidelines, regulations and standards of care
Anti-depressive effectiveness of olanzapine, quetiapine, risperidone and ziprasidone: a pragmatic, randomized trial
<p>Abstract</p> <p>Background</p> <p>Efficacy studies indicate anti-depressive effects of at least some second generation antipsychotics (SGAs). The Bergen Psychosis Project (BPP) is a 24-month, pragmatic, industry-independent, randomized, head-to-head comparison of olanzapine, quetiapine, risperidone and ziprasidone in patients acutely admitted with psychosis. The aim of the study is to investigate whether differential anti-depressive effectiveness exists among SGAs in a clinically relevant sample of patients acutely admitted with psychosis.</p> <p>Methods</p> <p>Adult patients acutely admitted to an emergency ward for psychosis were randomized to olanzapine, quetiapine, risperidone or ziprasidone and followed for up to 2 years. Participants were assessed repeatedly using the Positive and Negative Syndrome Scale - Depression factor (PANSS-D) and the Calgary Depression Scale for Schizophrenia (CDSS).</p> <p>Results</p> <p>A total of 226 patients were included. A significant time-effect showing a steady decline in depressive symptoms in all medication groups was demonstrated. There were no substantial differences among the SGAs in reducing the PANSS-D score or the CDSS sum score. Separate analyses of groups with CDSS sum scores > 6 or ≤6, respectively, reflecting degree of depressive morbidity, revealed essentially identical results to the primary analyses. There was a high correlation between the PANSS-D and the CDSS sum score (r = 0.77; p < 0.01).</p> <p>Conclusions</p> <p>There was no substantial difference in anti-depressive effectiveness among olanzapine, quetiapine, risperidone or ziprasidone in this clinically relevant sample of patients acutely admitted to hospital for symptoms of psychosis. Based on our findings we can make no recommendations concerning choice of any particular SGA for targeting symptoms of depression in a patient acutely admitted with psychosis.</p> <p>Trial Registration</p> <p>ClinicalTrials.gov ID; URL: <url>http://www.clinicaltrials.gov/</url>: <a href="http://www.clinicaltrials.gov/ct2/show/NCT00932529">NCT00932529</a></p
Adherence and profile of non-persistence in patients treated for osteoporosis—a large-scale, long-term retrospective study in The Netherlands
The Global Longitudinal Study of Osteoporosis in Women (GLOW): rationale and study design
SUMMARY: The Global Longitudinal study of Osteoporosis in Women (GLOW) is a prospective cohort study involving 723 physicians and 60,393 women subjects \u3eor=55 years. The data will provide insights into the management of fracture risk in older women over 5 years, patient experience with prevention and treatment, and distribution of risk among older women on an international basis.
INTRODUCTION: Data from cohort studies describing the distribution of osteoporosis-related fractures and risk factors are not directly comparable and do not compare regional differences in patterns of patient management and fracture outcomes.
METHODS: The GLOW is a prospective, multinational, observational cohort study. Practices typical of each region were identified through primary care networks organized for administrative, research, or educational purposes. Noninstitutionalized patients visiting each practice within the previous 2 years were eligible. Self-administered questionnaires were mailed, with 2:1 oversampling of women \u3eor=65 years. Follow-up questionnaires will be sent at 12-month intervals for 5 years.
RESULTS: A total of 723 physicians at 17 sites in ten countries agreed to participate. Baseline surveys were mailed (October 2006 to February 2008) to 140,416 subjects. After the exclusion of 3,265 women who were ineligible or had died, 60,393 agreed to participate.
CONCLUSIONS: GLOW will provide contemporary information on patterns of management of fracture risk in older women over a 5-year period. The collection of data in a similar manner in ten countries will permit comparisons of patient experience with prevention and treatment and provide insights into the distribution of risk among older women on an international basis
Recommended from our members
A lightweight framework for secure life-logging in smart environments
As the world becomes an interconnected network where objects and humans interact with each other, new challenges and threats appear in the ecosystem. In this interconnected world, smart objects have an important role in giving users the chance for life-logging in smart environments. However, smart devices have several limitations with regards to memory, resources and computation power, hindering the opportunity to apply well-established security algorithms and techniques for secure life-logging on the Internet of Things (IoT) domain. The need for secure and trustworthy life-logging in smart environments is vital, thus, a lightweight approach has to be considered to overcome the constraints of smart objects. The purpose of this paper is to present in details the current topics of life-logging in smart environments, while describing interconnection issues, security threats and suggesting a lightweight framework for ensuring security, privacy and trustworthy life-logging. In order to investigate the efficiency of the lightweight framework and the impact of the security attacks on energy consumption, an experimental test-bed was developed including two interconnected users and one smart attacker, who attempts to intercept transmitted messages or interfere with the communication link. Several mitigation factors, such as power control, channel assignment and AES-128 encryption were pplied for secure life-logging. Finally, research into the degradation of the consumed energy regarding the described intrusions is presented
Protocol for the Osteoporosis Choice trial. A pilot randomized trial of a decision aid in primary care practice
- …